Kronos Bio (KRON) Q3 2024 earnings summary

Executive summary

• Discontinued lead clinical asset istisociclib after adverse neurological events in Phase 1/2 trial for ovarian cancer; five of seven patients experienced neurological adverse events, leading to dose reductions or discontinuations.

• Board approved plan to evaluate strategic alternatives, including potential sale, merger, acquisition, asset sale, or liquidation, with exclusive financial advisor engagement.

• Pipeline focus shifted to preclinical assets KB-9558 (multiple myeloma, HPV-driven tumors) and KB-7898 (Sjogren's disease, autoimmune), both in IND-enabling studies.

• Corporate restructuring in Q1 2024 eliminated three executive roles and reduced workforce by 21% to contain costs; significant expense reduction strategies to be implemented.

Financial highlights

• Revenue for Q3 2024 was $2.4M, up from $0.9M in Q3 2023, driven by increased activity under the Genentech collaboration; no revenue reported in some sources.

• Net loss for Q3 2024 was $14.1M, or $0.23 per share, including $2.0M in non-cash stock-based compensation; nine-month net loss was $60.3M, down from $87.4M year-over-year.

• Operating expenses for the nine months ended September 30, 2024, were $73.3M, down from $98.5M in the prior year period, reflecting lower R&D and G&A costs.

• Cash, cash equivalents, and investments totaled $124.9M as of September 30, 2024, down from $174.99M at December 31, 2023.

• R&D expenses were $12.3M and G&A expenses $5.8M in Q3 2024, including $0.8M and $1.2M in non-cash stock-based compensation, respectively.

Outlook and guidance

• KB-9558 expected to be IND-ready by end of 2024; KB-7898 has begun IND-enabling studies.

• Current cash and investments expected to fund operations for at least 12 months from the financial statement issuance date; additional capital will be required if a strategic transaction is not completed.

• No further updates on strategic review unless a specific course of action is approved.